Finanzen von bioAffinity Technologies Inc (BIAF)BIAFbioAffinity Technologies Inc

bioAffinity Technologies Inc (BIAF) generates its revenue primarily from Laboratory services, which accounts for 100.0% of total sales, equivalent to $1.45M. Understanding this concentration is critical for investors evaluating how BIAF navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, bioAffinity Technologies Inc maintains a gross margin of 23.91%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -220.77%, while the net margin is -222.83%. These profitability ratios, combined with a Return on Equity (ROE) of -1860.15%, provide a clear picture of how effectively BIAF converts its operational activities into shareholder value.

In the context of the broader market, BIAF competes directly with industry leaders such as GCTK and VBIO. With a market capitalization of $3.90M, it holds a significant position in the sector. When comparing efficiency, BIAF's gross margin of 23.91% stands against GCTK's N/A and VBIO's N/A. Such benchmarking helps identify whether bioAffinity Technologies Inc is trading at a premium or discount relative to its financial performance.

The company has been experiencing consistent losses, with a net income of -$3.37 million in Q2 2026 and a gross margin that has fluctuated, currently at 23.91%. This indicates challenges in profitability and operational efficiency.